339 related articles for article (PubMed ID: 24938720)
1. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
[TBL] [Abstract][Full Text] [Related]
3. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
[TBL] [Abstract][Full Text] [Related]
4. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
[TBL] [Abstract][Full Text] [Related]
7. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A; Schulz A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
[TBL] [Abstract][Full Text] [Related]
8. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
[TBL] [Abstract][Full Text] [Related]
11. A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis.
Sanders DN; Kanazono S; Wininger FA; Whiting RE; Flournoy CA; Coates JR; Castaner LJ; O'Brien DP; Katz ML
Genes Brain Behav; 2011 Oct; 10(7):798-804. PubMed ID: 21745338
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution.
Vuillemenot BR; Kennedy D; Reed RP; Boyd RB; Butt MT; Musson DG; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
Toxicol Appl Pharmacol; 2014 May; 277(1):49-57. PubMed ID: 24642058
[TBL] [Abstract][Full Text] [Related]
15. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.
Munesue Y; Ageyama N; Kimura N; Takahashi I; Nakayama S; Okabayashi S; Katakai Y; Koie H; Yagami KI; Ishii K; Tamaoka A; Yasutomi Y; Shimozawa N
Exp Neurol; 2023 May; 363():114381. PubMed ID: 36918063
[TBL] [Abstract][Full Text] [Related]
16. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
Katz ML; Tecedor L; Chen Y; Williamson BG; Lysenko E; Wininger FA; Young WM; Johnson GC; Whiting RE; Coates JR; Davidson BL
Sci Transl Med; 2015 Nov; 7(313):313ra180. PubMed ID: 26560358
[TBL] [Abstract][Full Text] [Related]
17. A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis.
Awano T; Katz ML; O'Brien DP; Sohar I; Lobel P; Coates JR; Khan S; Johnson GC; Giger U; Johnson GS
Mol Genet Metab; 2006 Nov; 89(3):254-60. PubMed ID: 16621647
[TBL] [Abstract][Full Text] [Related]
18. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
[No Abstract] [Full Text] [Related]
19. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
